Dianthus Therapeutics (DNTH) Enterprise Value (2017 - 2025)

Dianthus Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$403.5 million for Q4 2025.

• In Q4 2025, Enterprise Value fell 47.03% year-over-year to -$403.5 million; the TTM figure through Dec 2025 stood at -$403.5 million (down 47.03% YoY), while the FY2025 annual figure was -$403.5 million, down 47.03% from the prior year.
• Enterprise Value was -$403.5 million for Q4 2025 at Dianthus Therapeutics, roughly flat from -$402.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$25.0 million in Q1 2023 to a low of -$403.5 million in Q4 2025.
• Historically, Enterprise Value has averaged -$212.5 million across 5 years, with a median of -$191.2 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 84.04% in 2023, then slumped 1408.63% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$176.9 million in 2021, then surged by 57.33% to -$75.5 million in 2022, then sank by 130.12% to -$173.7 million in 2023, then slumped by 57.95% to -$274.4 million in 2024, then slumped by 47.03% to -$403.5 million in 2025.
• The last three Enterprise Value figures came in at -$403.5 million (Q4 2025), -$402.6 million (Q3 2025), and -$256.1 million (Q2 2025), per Business Quant data.